Akero Therapeutics Inc (AKRO) Stock
AKRO is no longer traded. Akero Therapeutics was acquired by Novo Nordisk (NVO) on December 9, 2025.
Each AKRO share was exchanged for $54.00 in cash plus one contingent value right worth up to $6.00. Prices on this page are historical; the last trade was December 8, 2025 at $54.65.
See Novo Nordisk (NVO) stock →Akero Therapeutics stock price history
AKRO final trading statistics
- Final close
- $54.65
- Final trading day
- Dec 8, 2025
- Market cap at delisting
- $4.50B
- Shares outstanding
- 82.32M
- Final 52-week range
- $21.34 – $58.40
- Avg. volume (final 3 mo.)
- 2,551,414
- All-time high (split-adj.)
- $57.56 · Feb 2025
- All-time low (split-adj.)
- $8.00 · Jun 2022
- Return since IPO
- +198.3%
- Beta
- -0.40
- Book value / share
- $11.95
- Price / book
- 4.57
Akero Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $0.00 | -$252.1M | -$3.75 |
| FY2023 | $0.00 | -$151.8M | -$2.85 |
| FY2022 | $0.00 | -$112.0M | -$2.92 |
| FY2021 | $0.00 | -$100.7M | -$2.89 |
| FY2020 | $0.00 | -$79.2M | -$2.48 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Akero Therapeutics Inc
Akero Therapeutics, Inc. engages in developing transformational treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Therapeutics, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. As of December 9, 2025, Akero Therapeutics, Inc. operates as a subsidiary of Novo Nordisk A/S.
Akero Therapeutics stock FAQ
What happened to Akero Therapeutics stock?
Akero Therapeutics was acquired by Novo Nordisk (NVO) on December 9, 2025. Shareholders received $54.00 in cash plus one contingent value right worth up to $6.00 for each share. AKRO stock stopped trading on the Nasdaq, with a final close of $54.65 on December 8, 2025.
What did Akero Therapeutics shareholders receive?
Each AKRO share was converted into $54.00 in cash plus one contingent value right worth up to $6.00. The deal was valued at up to about $5.2 billion.
Is AKRO stock still trading?
No. AKRO was delisted from the Nasdaq on December 9, 2025 and no longer trades on a U.S. exchange.
What was the last price of AKRO stock?
AKRO closed at $54.65 on its final trading day, December 8, 2025, for a market value of about $4.50B.
What were Akero Therapeutics's revenue and earnings in its last full fiscal year?
Akero Therapeutics reported revenue of $0.00 and net income of -$252.1M in fiscal 2024, its last full year as a public company.
When did Akero Therapeutics go public?
Akero Therapeutics Inc stock began trading on June 20, 2019.